stage

AIN
IonescuTx

IonescuTx

location_on 西部 ,  美国

请注意：
投资于早期阶段的企业存在风险，包括流动性不足、无分红、投资损失及股权稀释等。因此，此类投资应仅作为多元化投资组合的一部分进行。本平台仅面向具备足够专业知识、能够理解相关风险并自行作出投资决策的投资者。我们鼓励投资者自行审阅与评估各项投资，并根据自身判断决定是否参与。本网站所提供的信息仅供参考，我们无法保证其准确性或完整性。我们强烈建议投资者在进行任何投资前，与持牌专业人士完成尽职调查。本平台不提供任何法律或税务方面的建议。

简要概述

The goal of IonescuTx is to discover disease-modifying small-molecule therapeutics for late-onset Alzheimer's Disease (LOAD). We are focused on correcting ApoE4 function to stop lipid dysregulation in the brain that leads to neurodegeneration.

亮点

  • ApoE4 is the strongest genetic risk factor for Alzheimer's disease
  • Current approaches focus on plaques and aggregates, which lack efficacy
  • Substantial evidence suggests ApoE4 causes Alzheimer's disease progression
  • Our approach is to correct ApoE4 function to stop Alzheimer's progression
  • We will discover and develop small molecule modulators of ApoE4

概览

目标 HK$ 78,000,000
最低标准。 HK$ 80,000
融资已到位。 HK$ 0
过往融资轮次 HK$ 0
阶段 初创前期/研发阶段
投资人角色 任何。

提出一个问题。
有問題嗎？

相似项目

The in Between

The in Between

location_on豪登省, 南非

Serving South Africans unable to afford private services but are able to pay for semi-private alternatives, such as affordable schools. A joint pharmacy venture with the State—providing not free but reliable, accessible, and fairly priced medicines.

  • Quality education for families between public & private options
  • Smaller classes → better student results
  • Affordable, fast access to essential medication

HK$13,000,000

融资目标

HK$45,000

最低投资额
了解更多
Cure For Paralysis

Cure For Paralysis

location_on以色列

Matricelf develops the first autologous (self) neural implant to repair spinal cord injuries. Backed by strong preclinical data and heading toward First-in-Human trials in early 2026, a key inflection point.

  • The 1st to develop functional neuronal tissue (Micro-Spinal Cord)
  • Autologous (self). Made from the patient own cells. No rejection.
  • 3d structure to accelerate integration.

HK$23,000,000

融资目标

HK$200,000

最低投资额
了解更多
MediPoint UK Limited

MediPoint UK Limited

location_on伦敦, 英国

MediPoint facilitates easy access to licensed Pharmaceutical Products in the UK at competitive prices.

  • 7 Licences already obtained
  • 5 Licences already applied for
  • Major customers secured

HK$21,000,000

融资目标

HK$2,600,000

最低投资额
了解更多
Loading…
Loading the web debug toolbar…
Attempt #